peficitinib   Click here for help

GtoPdb Ligand ID: 8315

Synonyms: ASP015K | JNJ-54781532
Approved drug Immunopharmacology Ligand
peficitinib is an approved drug (Japan (2019))
Compound class: Synthetic organic
Comment: Peficitinib is an oral Janus kinase inhibitor [5] that was developed for potential anti-inflammatory action in autoimmune diseases including rheumatoid arthritis [6-7], psoriasis and ulcerative colitis [3].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 4
Rotatable bonds 3
Topological polar surface area 104.03
Molecular weight 326.17
XLogP 1.83
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES NC(=O)c1cnc2c(c1NC1C3CC4CC1CC(C3)(C4)O)cc[nH]2
Isomeric SMILES NC(=O)c1cnc2c(c1NC1[C@@H]3CC4C[C@H]1CC(C3)(C4)O)cc[nH]2
InChI InChI=1S/C18H22N4O2/c19-16(23)13-8-21-17-12(1-2-20-17)15(13)22-14-10-3-9-4-11(14)7-18(24,5-9)6-10/h1-2,8-11,14,24H,3-7H2,(H2,19,23)(H2,20,21,22)/t9?,10-,11+,14?,18?
No information available.
Summary of Clinical Use Click here for help
Peficitinib was approved as a treatment for rheumatoid arthritis in 2019 [4], but is not yet (March 2021) approved by the FDA or EMA.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
The Janus kinase (JAK) enzymes play a key role in cytokine signalling, which is involved in the pathological symptoms of immune-mediated disorders such as rheumatoid arthritis (RA). Peficitinib has been reported to inhinit all four JAKs at low nanomolar concentrations, although this data is not yet published in a peer reviewed article (see ASP015K: A Novel JAK Inhibitor Demonstrated Potent Efficacy in Adjuvant-Induced Arthritis Model in Rats, an abstract from the proceedings of the American College of Rheumatology/Association of Rheumatology Health Professionals, Annual Scientific Meeting, Washington DC, November 9-14, 2012).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02308163 A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDs Phase 3 Interventional Astellas Pharma Inc 8
NCT01711814 A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study Phase 2 Interventional Astellas Pharma Inc 1